Accutane Mechanism of Action Explained Step by Step
HealthRX.com
Isotretinoin cuts sebum, but its exact mechanism is unknown
Key numbers
- 48.2%Reduction in acetate incorporation into lipids by 13-cis-retinoic acid in cultured human sebocytesSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 8, 2026
- 10,004 ng·h/mLAUC after a high-fat meal in 74 healthy adults given a single 80 mg dose (fasted: 3,703 ng·h/mL)Source: dailymed.nlm.nih.gov, as cited Nov 8, 2026
- 42%Share of the 0.1 mg/kg/day group in a 150-patient trial that needed retreatmentSource: pubmed.ncbi.nlm.nih.gov, as cited Nov 8, 2026
From the public record
Published studies on isotretinoin mechanism of action
Goldstein (1982) reported an 88.4% sebum decrease and sebaceous gland shrinkage in seven men with severe acne after 16 weeks, suggesting sebostasis may not be the sole explanation for isotretinoin's mechanism. Dalziel (1987) found sebaceous glands reduced in volume while follicular duct epithelium was unchanged.
| Measure | Value | Note |
|---|---|---|
| Goldstein 1982, randomized controlled trial, Fifty-six men, severe acne | Marked sebum suppression vs etretinate | Isotretinoin markedly suppressed sebum production, while etretinate had little effect on sebum. PMID 6461679 |
| Farrell 1980, Double-blind trial, Fourteen patients | Marked sebum decrease | Sebum production fell in all patients, usually evident within 2 weeks of starting therapy. PMID 6451637 |
| Strauss 1982, controlled clinical trial, twenty patients | Sebum inhibition lasted after stopping | Sebum stayed 30% to 80% below pretreatment for up to 80 weeks in eight subjects. PMID 6461678 |
| Dalziel 1987, clinical investigation | Sebaceous glands shrank, ducts did not | Sebaceous glands were significantly reduced in volume, while follicular duct epithelium was unchanged. PMID 2960370 |
| Goldstein 1982, clinical observations, seven men with severe acne | 88.4% sebum decrease at 16 weeks | Sebum fell 88.4% and sebaceous glands shrank, but sebostasis may not be the sole mechanism. PMID 6213204 |
| Nelson 2009, microarray gene expression study, eight acne patients | Lipid enzyme genes downregulated | Lipid metabolizing enzyme genes were downregulated at 8 weeks. PMID 20436886 |
How this was calculated
PubMed title and abstract search on 2026-11-13 for isotretinoin, Accutane, Absorica with mechanism of action, pharmacodynamic, sebaceous gland, sebum production: 323 records, 14 abstracts read, 6 listed, each row summarising its own abstract.
Isotretinoin mechanism of action: 6 of 323 PubMed records.
See the public record for Isotretinoin
At a glance
- Drug class / Oral retinoid, 13-cis-retinoic acid [2]
- Label on mechanism / Inhibits sebaceous gland function and keratinization [1]
- What clearing tracks with / A reduction in sebum secretion [1]
- Label's own explanation / Reduced sebaceous gland size plus inhibited gland differentiation [1]
- How long the sebum drop lasts / Temporary; related to dose and duration [2]
- Main circulating metabolites / 4-oxo-isotretinoin, retinoic acid (tretinoin), 4-oxo-tretinoin [2]
- Labeled course / 0.5 to 1 mg/kg/day of Absorica in two divided doses for 15 to 20 weeks [1]
- Cumulative dose target / Not stated in the label; 120 to 150 mg/kg comes from the medical literature [1][3]
What the label actually says
The Absorica and Absorica LD prescribing information states that the exact mechanism of action is unknown [1]. It describes isotretinoin as a retinoid that inhibits sebaceous gland function and keratinization [1].
Clinical improvement in nodular acne occurs in association with a reduction in sebum secretion, and that decrease is temporary and reflects a reduction in sebaceous gland size and an inhibition of sebaceous gland differentiation [1]. The older Accutane-type labeling says the same thing and adds that the decrease is related to the dose and duration of treatment [2].
Questions worth asking
Step 1: Getting isotretinoin into the blood
Absorica and Absorica LD can be taken with or without meals, while the older-format isotretinoin labels say to take the capsules with food because fasting significantly decreases absorption [1][2].
In a crossover study of 74 healthy adults given a single 80 mg dose, a high-fat meal more than doubled exposure: AUC was 10,004 ng·h/mL fed versus 3,703 ng·h/mL fasted, and Cmax was 862 versus 301 ng/mL, with the same roughly 21-hour half-life either way [2]. The drug is more than 99.9% bound to plasma proteins, mainly albumin [2].
Step 2: Metabolites that also have retinoid activity
Isotretinoin is converted to at least three plasma metabolites: 4-oxo-isotretinoin, retinoic acid (tretinoin) and 4-oxo-tretinoin [2]. At steady state, exposure to 4-oxo-isotretinoin is about 3.4 times that of the parent drug [2]. All of these metabolites have retinoid activity, in some in vitro models greater than the parent drug, although the label calls the clinical significance of those models unknown [2].
Retinoic acid and 13-cis-retinoic acid are geometric isomers that interconvert, so giving one gives rise to the other [2]. In vitro work points to CYP2C8, 2C9, 3A4 and 2B6 as the main enzymes involved in metabolism [2].
Step 3: Sebum output falls
This is the change that tracks with clearing. In a double-blind dose-response study of 48 acne patients, oral 13-cis-retinoic acid produced marked clinical improvement together with a fall in sebum excretion rate and in the production rate of free fatty acids [4]. Microbial numbers also fell significantly, with a larger drop in propionibacteria than in aerobic bacteria, but that decline happened after sebum and free fatty acid production had already dropped, which the authors said suggests the effect on bacteria is secondary to the change in sebum [4].
The label says the decrease in sebum secretion is temporary and related to dose and duration of treatment [2].
Step 4: The gland gets smaller and differentiates less
The label says the sebum fall reflects two changes in the gland itself: a reduction in sebaceous gland size and an inhibition of sebaceous gland differentiation [1].
Laboratory work on cultured human sebocytes shows what retinoids do to those cells directly. Both 13-cis-retinoic acid and all-trans-retinoic acid decreased sebocyte proliferation in a dose- and time-dependent way, and 13-cis-retinoic acid was the most potent inhibitor of acetate incorporation into lipids, with a 48.2% reduction, followed by all-trans-retinoic acid at 38.6% and acitretin at 27.5% [5]. Synthesis of triglycerides, wax and stearyl esters and free fatty acids fell, squalene synthesis was unaffected and cholesterol synthesis rose slightly [5]. These are cultured cells, not patients, so they show what retinoids can do to a sebocyte rather than what is proven to happen during a course.
Step 5: Keratinization
The label names keratinization as the second process isotretinoin inhibits, alongside sebaceous gland function [1]. Its mechanism section does not say which keratinization steps are involved. The same cultured-sebocyte work found that retinoids changed keratin expression in vitro, for example down-regulating keratin 5 and up-regulating keratin 17 [5].
Clinically, the label approves isotretinoin for severe recalcitrant nodular acne with multiple inflammatory nodules 5 mm or larger in patients 12 years and older who have not responded to conventional therapy, including systemic antibiotics [1].
Step 6: Inflammation and immune effects
Retinoids as a class affect epidermal cell growth and differentiation and sebaceous gland activity, and they have immunomodulatory and anti-inflammatory properties [6]. That is a class-level statement, not a step-by-step account of isotretinoin in acne.
The in vitro work showing reduced TLR-2 expression in skin explants was done with adapalene, a different retinoid, not oral isotretinoin [7].
One hypothesis ties much of the drug's behavior together. It proposes that isotretinoin acts as a prodrug, isomerizing to all-trans-retinoic acid, which induces apoptosis in cultured sebaceous gland cells, and that upregulation of FoxO transcription factors could explain the therapeutic, adverse and teratogenic effects through a single pathway [8]. The author presents this as a scientific hypothesis supported by indirect evidence, not as an established mechanism.
Step 7: Receptors
Retinoids interact with cytosolic proteins and with two classes of nuclear receptors, RARs and RXRs, and skin mainly expresses RAR gamma and RXR alpha [6]. This is general retinoid pharmacology from a review of the retinoid class [6]; the label does not describe receptor binding as the mechanism of isotretinoin in acne [1].
Isotretinoin: the molecule in 3D
- Carbon
- Oxygen
Formula, weight and what this structure shows
| Molecular formula | C20H28O2 |
|---|---|
| Molecular weight | 300.4 g/mol |
| Atoms shown | 22 (Carbon 20, Oxygen 2). Hydrogen atoms are left out. |
| Bonds shown | 22 |
| Rotatable bonds | 5 |
| Hydrogen bond donors | 1 |
| Hydrogen bond acceptors | 2 |
| Polar surface area | 37.3 square angstroms |
| XLogP3 (higher is more fat-soluble) | 6.3 |
| How the shape was found | Computed by PubChem as one low-energy shape. The real molecule flexes between many shapes, and this is not a measured structure. |
Labeled course length and dose
The label doses Absorica at 0.5 to 1 mg/kg/day in two divided doses for 15 to 20 weeks, with Absorica LD at 0.4 to 0.8 mg/kg/day. For adults with very severe disease (scarring or trunk involvement), it allows up to 2 mg/kg/day of Absorica or 1.6 mg/kg/day of Absorica LD as tolerated, and it says once-daily dosing is not recommended [1]. The label says that if the total nodule count has fallen by more than 70% before 15 to 20 weeks, the drug may be discontinued, and that a second course may be started after at least 2 months off treatment if severe nodular acne persists or recurs, because acne may keep improving after a course [1][2]. The older labeling notes that a single 15-to-20-week course has been shown to result in complete and prolonged remission in many patients [2].
The dose question has been tested. In a double-blind multicentre trial of 150 patients with treatment-resistant nodulocystic acne, 0.1, 0.5 and 1 mg/kg/day all produced a highly significant clinical response with no significant difference in response between the doses, but 42% of the 0.1 mg/kg/day group needed retreatment, which led the authors to conclude that higher doses are indicated [9].
The 120 to 150 mg/kg cumulative dose often quoted is not in the label, which states no cumulative mg/kg target [1][3]. It comes from the literature. A 2026 single-centre, single-blind randomized trial compared 120 with 150 mg/kg in moderate-to-severe cystic acne: lesion counts and severity improved comparably (all p > 0.20), 12-month relapse was 26.7% at 120 mg/kg versus 32.3% at 150 mg/kg (p = 0.619), and scarring did not worsen [3]. The authors listed a single-centre design and retrospective trial registration as limitations [3].
Teratogenicity and iPLEDGE
The boxed warning says isotretinoin can cause life-threatening birth defects, that there is an extremely high risk of defects if pregnancy occurs while taking any amount even for short periods, and that potentially any exposed fetus can be affected [1]. The label lists malformations of the face, eyes, ears, skull, central nervous system, cardiovascular system, thymus and parathyroid glands, and reports IQ scores below 85 in children exposed in utero [1].
Because of that risk, isotretinoin is available only through the iPLEDGE REMS [1]. Every patient is enrolled. Patients who can get pregnant are subject to pregnancy-testing and pregnancy-prevention requirements, must demonstrate comprehension before each prescription, and must obtain the prescription within 7 days of the pregnancy-test collection, while patients who cannot get pregnant must not share the drug or donate blood [1]. FDA approved modifications to the program on 2026-02-09, including, with prescriber permission, home pregnancy tests during and after treatment; FDA's page current as of 2026-06-16 gives 2026-11-15 as the planned implementation date [10][11].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
Does isotretinoin kill Cutibacterium acnes directly?
What receptors does isotretinoin act on?
Is 120 to 150 mg/kg a labeled dose?
Why does food matter for how the drug behaves?
Is oral isotretinoin the same drug as topical tretinoin?
References
Show all 11 referencesHide references
- U.S. National Library of Medicine, DailyMed. Absorica and Absorica LD isotretinoin capsules (Sun Pharma) prescribing information. Absorica and Absorica LD isotretinoin capsules (Sun Pharma) label
- U.S. National Library of Medicine, DailyMed. Accutane-format isotretinoin label (older non-PLR format) prescribing information. Accutane-format isotretinoin label (older non-PLR format) label
- Cascio Ingurgio R, Alfano A, Costanzo A, Cronk JS, Cummins R, Daniel BS, et al. Cumulative isotretinoin dosing, treatment response and acne relapse: A randomized controlled trial. J Eur Acad Dermatol Venereol. 2026.
- King K, Jones DH, Daltrey DC, Cunliffe WJ. A double-blind study of the effects of 13-cis-retinoic acid on acne, sebum excretion rate and microbial population. Br J Dermatol. 1982;107(5):583-90.
- Zouboulis CC, Korge B, Akamatsu H, Xia LQ, Schiller S, Gollnick H, et al. Effects of 13-cis-retinoic acid, all-trans-retinoic acid, and acitretin on the proliferation, lipid synthesis and keratin expression of cultured human sebocytes in vitro. J Invest Dermatol. 1991;96(5):792-7.
- Orfanos CE, Zouboulis CC, Almond-Roesler B, Geilen CC. Current use and future potential role of retinoids in dermatology. Drugs. 1997;53(3):358-88.
- Tenaud I, Khammari A, Dreno B. In vitro modulation of TLR-2, CD1d and IL-10 by adapalene on normal human skin and acne inflammatory lesions. Exp Dermatol. 2007;16(6):500-6.
- Melnik BC. Isotretinoin and FoxO1: A scientific hypothesis. Dermatoendocrinol. 2011;3(3):141-65.
- Strauss JS, Rapini RP, Shalita AR, Konecky E, Pochi PE, Comite H, et al. Isotretinoin therapy for acne: results of a multicenter dose-response study. J Am Acad Dermatol. 1984;10(3):490-6.
- iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) | FDA.
- Questions and Answers on the iPLEDGE REMS | FDA.